APA (7th ed.) Citation

N, T., C, S., P, A., E, v. d. T., M, O., N, K., . . . J, O. (2025). Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(5), 513. https://doi.org/10.1200/JCO.24.00529

Chicago Style (17th ed.) Citation

N, Turner, et al. "Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 5 (2025): 513. https://doi.org/10.1200/JCO.24.00529.

MLA (9th ed.) Citation

N, Turner, et al. "Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 5, 2025, p. 513, https://doi.org/10.1200/JCO.24.00529.